Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.
Director of the National Cancer Institute, Harold Varmus, MD'66, talked about the challenges and goals of precision medicine's efforts to tackle cancer.